An fMRI Study of Treatment Optimization Comparing Two Disease Modifying Therapies Used to Treat Relapsing Remitting Multiple Sclerosis

NCT00398528 · clinicaltrials.gov ↗

TERMINATED

Status

48

Enrollment

INDUSTRY

Sponsor class

Stopped rate of enrollment

Conditions

Relapsing-Remitting Multiple Sclerosis

Interventions

DRUG: Glatiramer acetate, (Copaxone®)
DRUG: IFN-β-1a, (Avonex®)

Sponsor

Neurognostics